This proposal from the Johns Hopkins University is to continue as the Data Coordinating Center (DCC) of the Gastroparesis Clinical Research Consortium (GPCRC) to support the clinical centers as they complete three treatment trials (NORIG, GLUMIT-DG, APRON) and continue to gather biospecimens and data for patients with gastroparesis and related disorders in the Gastroparesis Registry. In addition, the DCC will support the Pathological Basis of Gastroparesis Study conducted by Dr. Farrugia at the Mayo Clinic in Rochester, MN for identification ofthe molecular factors involved in pathogenesis of gastroparesis. The goal ofthe GpCRC sponsored by the NIDDK since 2006 is to focus on the etiology, treatment strategies, and clinical course of gastroparesis. The DCC will continue to support the GpCRC and will be responsible for supporting any protocol development or modifications;providing sample size calculations, statistical advice, questionnaires, and data analysis;supporting development, implementation, and maintenance of a data base of clinical information and blood samples;developing or modifying any data monitoring plans;supporting manuscript preparation;and providing overall study coordination and quality assurance, including coordination ofthe activities and meetings of the Steering Committee (SC). The DCC will prepare or modify protocols for submission to the Data and Safety Monitoring Board (DSMB) and the SC for their approval prior to the implementation of any study protocols or protocol change. The DCC will be responsible for preparation of documents for submission to the Food and Drug Administration (FDA) in support of Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications on behalf of the GPCRC. The DCC will prepare all reports including data reports for review by the DSMB at their meetings. The DCC will be responsible for acquiring and administering subcontracts as needed. The DCC will continue to work with the NIDDK Biosample, Genetic and Data Repositories and the clinical centers to coordinate procedures for coding, shipping, processing, receipt, and storage of study samples that are to be maintained in the Repositories.
Gastroparesis Consortium's research so far underscores the public health significance of gastroparesis including the need to develop effective methods for management of gastroparesis, the need to identify patients who are at risk of progression to more severe gastroparesis (including patients who are unable to maintain oral nutrition), and the need to identify the key cellular changes that lead to gastroparesis.
|Calles-Escandón, Jorge; Koch, Kenneth L; Hasler, William L et al. (2018) Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. PLoS One 13:e0194759|
|Orthey, Perry; Yu, Daohai; Van Natta, Mark L et al. (2018) Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. J Nucl Med 59:691-697|
|Hasler, W L; May, K P; Wilson, L A et al. (2018) Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil 30:|
|Pasricha, Pankaj J; Yates, Katherine P; Sarosiek, Irene et al. (2018) Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology 154:65-76.e11|
|Parkman, H P; Hallinan, E K; Hasler, W L et al. (2017) Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motil 29:|
|Gibbons, Simon J; Grover, Madhusudan; Choi, Kyoung Moo et al. (2017) Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLoS One 12:e0187772|
|Grover, M; Bernard, C E; Pasricha, P J et al. (2017) Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. Neurogastroenterol Motil 29:|
|Koch, K L; Hasler, W L; Yates, K P et al. (2016) Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. Neurogastroenterol Motil 28:1001-15|
|Parkman, H P; Hallinan, E K; Hasler, W L et al. (2016) Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil 28:1902-1914|
|Farrugia, Gianrico (2015) Histologic changes in diabetic gastroparesis. Gastroenterol Clin North Am 44:31-8|
Showing the most recent 10 out of 33 publications